In contrast, treatment with SMGGT (100 and 500 mg/kg) significantly decreased the expression of TNF-α, IL-4, and VEGF in skin lysates, and the SMGGT100 group showed lower levels of IL-13 than the AD + SD group (Figure 2(a)). The gene discussed is TNF; the disease is Alzheimer disease.